Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35338549/
1 CHIP, Center of Excellence for Health, Immunity and Infections, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 2 Department of Infectious Diseases 144, Hvidovre University Hospital, Copenhagen, Denmark. 3...
Conclusions: In 2021, the EACS Guidelines were updated extensively and broadened to include new sections. The recommendations are available as a free app, in interactive web format and as an online pdf.
Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239219/
mBio. 2022 May-Jun; 13(3): e00577-22. Marianne Boutin, a , b Dani Vézina, a Shilei Ding, a Jérémie Prévost, a , b Annemarie Laumaea, a , b Lorie Marchitto, a ,...
Importance: FDA-approved fostemsavir, the prodrug for the active moiety small molecule temsavir (GSK 2616713 [formally BMS-626529]), acts as an attachment inhibitor by targeting the HIV-1 envelope (Env) and preventing CD4 interaction. Temsavir also stabilizes Env in its “closed,” functional state 1 conformation, which represents an ideal...
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211436/
Margaret Gartland, a Pedro Cahn, b Edwin DeJesus, c Ricardo Sobhie Diaz, d Robert Grossberg, e Michael Kozal, f Princy Kumar, g Jean-Michel Molina, h Fernando Mendo Urbina, i Marcia...
Conclusion/Relevance: In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks.
Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1
Source : https://www.clinicaltherapeutics.com/article/S0149-2918(22)00146-1/fulltext
Heavily treatment-experienced (HTE) people with multidrug-resistant HIV-1 have limited treatment options. Treatment with the first-in-class attachment inhibitor fostemsavir in addition to optimized background therapy (OBT) resulted in sustained virologic and...
Conclusions: Implications: Although matching-adjusted indirect comparison analyses have limitations, these results support the use of fostemsavir and OBT as an important treatment option in HTE people with multidrug-resistant HIV-1.
Virological failure and treatment switch after ART initiation among people living with HIV with and without routine viral load monitoring in Asia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36028921/
PLHIV from non-routine VL sites had a higher incidence of persistent VF and a low switching regimen rate, reflecting possible under-utilized VL testing.
Conclusions: PLHIV from non-routine VL sites had a higher incidence of persistent VF and a low switching regimen rate, reflecting possible under-utilized VL testing.